Cyclooxygenase as a target in lung cancer

Clinical Cancer Research

Volumn 10, Issue 12 II, 2004, Pages

  Brown, Joanne R ^a   DuBois, Raymond N ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GELATINASE A; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

ANGIOGENESIS; APOPTOSIS; CANCER CELL CULTURE; CANCER PREVENTION; CONFERENCE PAPER; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG CANCER; LUNG CARCINOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; TUMOR GROWTH;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; ISOENZYMES; LUNG NEOPLASMS; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SURVIVAL ANALYSIS;

EID: 3042665905     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040014     Document Type: Conference Paper

References (44)

1. Gupta RA, DuBois RN. Colorectal cancer and the cyclooxygenase pathway. Nat Rev Cancer 2001;1:11-21.
2. Koki A, Khan NK, Woerner BM, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 2002;507:177-84.
3. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
4. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30:73-81.
5. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 2002;8: 1035-62.
6. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
7. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
8. Fang HY, Lin TS, Lin JP, et al. Cyclooxygenase-2 in human non-small cell lung cancer. Eur J Surg Oncol 2003;29:171-7.
9. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of COX-isozymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-10.
10. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
11. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
12. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002;235:440-3.
13. Josephy PD, Chiu AL, Eling TE. Prostaglandin H synthase-dependent mutagenic activation of benzidine in a Salmonella typhimurium Ames tester strain possessing elevated N-acetyltransferase levels. Cancer Res 1989;49:853-6.
14. Kelley DJ, Mestre JR, Subbaramaiah K, et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis (Lond) 1997;18:795-9.
15. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995;83:493-501.
16. 1 delay in intestinal epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996;56:733-7.
17. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001;276:48997-9002.
18. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6:2006-11.
19. Yao R, Rioux N, Castonguay A, You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res 2000;26:731-42.
20. Chang HC, Weng CF. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol Rep 2001;8:1321-5.
21. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
22. Ohta Y, Tomita Y, Oda M, et al. Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 1999;68: 1034-8.
23. Guddo F, Fontanini G, Reina C, et al. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol 1999;30:788-94.
24. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998;37: 19-29.
25. Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Investig 1998;102:465-72.
26. Okada F, Rak JW, Croix BS, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998;95:3609-14.
27. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
28. Masferrer JL, Leahy KM, Koki AT. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000;7:1163-70.
29. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Investig 2000;105: 1589-94.
30. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276:20809-12.
31. Dohadwala M, Batra RK, Luo J, et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002;277:50828-33.
32. Dubinett SM, Sharma S, Huang M, et al. Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 2003;37:138-62.
33. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
34. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961-8.
35. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
36. 2 content in bronchoalveolar lavage fluid and intrathoracic malignancy. Chest 1994;106:166-72.
37. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5:138-46.
38. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002;9:693-5.
39. Moysich KB, Menezes RJ, Ronsani A, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002;2:31-7.
40. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J 2000;320:1642-6.
41. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis (Lond) 1997;18:1001-6.
42. Castonguay A, Rioux N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis (Lond) 1997;18:491-6.
43. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998;58:5354-60.
44. Kisley LR, Barrett BS, Bauer AK, et al. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 2002;62:6850-6.